The US Cell Expansion Market was valued at $2865.8 Million in 2024 and projected to reach to $5597.1 Million by 2029, representing a compound annual growth rate of 14.3%. The US cell expansion market is poised for sustained growth through 2029, driven by increasing FDA approvals of cell-based therapies, expanding clinical applications in oncology and regenerative medicine, and growing investment from major pharmaceutical companies.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
The US cell expansion market is valued at $2,865.8 million in 2024, with a projected CAGR of 14.3% through 2029, reaching $5,597.1 million. This nearly doubles the market size within five years, reflecting strong demand for cell therapy manufacturing infrastructure.
The US leads North America in regenerative medicine adoption, driven by FDA approvals, advanced manufacturing facilities, and significant R&D investments. Major biopharmaceutical companies are establishing state-of-the-art cell expansion centers across the country.
US healthcare providers and biotech firms are rapidly scaling cell therapy production capabilities. Investment in automated bioreactors, GMP-compliant facilities, and skilled workforce development is accelerating to meet growing clinical and commercial demand.
FDA's streamlined approval pathways for cell and gene therapies, combined with substantial NIH funding and venture capital investment, position the US as the global innovation hub for cell expansion technologies and therapeutic applications.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | MEDIA (Type) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 13.3% from 2024 to 2029 |
| Largest Segment | CONSUMABLES (Product) |
| Market Size Base Year (Billions) | ~USD 14.3 (2024) |
| Revenue Forecast (Billions) | ~USD 26.7 (2029) |
| Segments Covered | Product, Type, Usage |
3 segment dimensions are covered across the global market.
| Segment | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| HOSPITALS & DIAGNOSTIC LABORATORIES | 589.7 | 653.5 | 730 | 819.7 | 924.2 | 1042.5 | 1176.1 | 1336.3 | 12.9 |
| OTHER END USERS | 527.4 | 589 | 663.1 | 750.5 | 852.9 | 969.7 | 1102.7 | 1263 | 13.8 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 1848.6 | 2075.6 | 2349.5 | 2673.5 | 3054.3 | 3491 | 3990.5 | 4594.2 | 14.4 |
| RESEARCH & ACADEMIC INSTITUTES | 772.8 | 851 | 944.6 | 1053.8 | 1180.2 | 1322.3 | 1481.3 | 1671.2 | 12.1 |
| TOTAL | 3738.5 | 4169.1 | 4687.2 | 5297.5 | 6011.7 | 6825.4 | 7750.7 | 8864.6 | 13.6 |
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| PATHEON INC | Netherlands | Private Company | Drug product services (finished dosage manufacturing and packaging),Pharmaceutical development services,Drug substance services (API and biologics), |
| ALLERGAN PLC | Ireland | Private Company | US Specialized Therapeutics (incl. Medical Aesthetics & Eye Care),US General Medicine (GI, CNS, Women’s Health, Anti-infectives),International (All Therapeutic Areas), |
| EIKEN CHEMICAL CO., LTD. | Japan | Public Company | Fecal immunochemical test (FIT) reagents and analyzers,Microbiological reagents and media,Immunological and serological reagents, |
| MAXCYTE, INC | United States | Public Company | ExPERT GTx and STx instruments,ExPERT ATx and VLx instruments,Processing assemblies (PAs) and consumables, |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Laboratory Products and Biopharma Services,Life Sciences Solutions,Analytical Instruments, |
| DANAHER CORPORATION | United States | Public Company | Biotechnology (bioprocessing hardware, consumables, services),Life Sciences (instruments, genomics, automation, microscopy),Diagnostics (clinical instruments, consumables, software, services), |
| MERCK KGAA | Germany | Public Company | Life Science (reagents, consumables, bioprocessing, CDMO),Healthcare (prescription drugs and biopharmaceuticals),Electronics (semiconductor and display materials, equipment), |
| SARTORIUS AG | Germany | Public Company | Bioprocess solutions (bioreactors, cell culture, fluid management, process filtration),Analytical instruments and PAT (BLI, cytometry, live-cell imaging, SPR, data analytics),Lab products and services (filtration, purification, lab water, weighing, pipettes, microbiological testing), |
| CORNING INCORPORATED | United States | Public Company | Optical Communications (fiber, cable, hardware, connectivity),Display Technologies (LCD and OLED glass substrates),Specialty Materials (mobile device glass, optics, wafers, shielding), |
| LONZA | Switzerland | Public Company | Integrated Biologics (mammalian and drug product platforms),Advanced Synthesis (small molecules, HPAPIs, ADCs and bioconjugates),Specialized Modalities (cell & gene, microbial, bioscience, mRNA), |
| TERUMO CORPORATION | Japan | Public Company | Cardiac and Vascular Company,Medical Care Solutions Company,Blood and Cell Technologies Company, |
| EPPENDORF SE | Germany | Private Company | Liquid handling instruments and automation,Separation, PCR, and cold storage instrumentation,Consumables (tubes, tips, plates, plastics), |
| FUJIFILM CORPORATION | Japan | Public Company | Healthcare (medical systems, CDMO, pharma, regenerative medicine, cosmetics/supplements),Electronics (display, semiconductor, image sensor and functional materials, storage, industrial equipment),Business Innovation (office equipment, document solutions, graphic communications, inkjet), |
| BIO-TECHNE | United States | Public Company | Protein Sciences (reagents and proteomic tools),Diagnostics and Spatial Biology, |
| REPLIGEN CORPORATION | United States | Public Company | Chromatography systems, OPUS columns, resins and ligands,Filtration and perfusion (XCell ATF, TangenX, KrosFlo, TFDF, ProConnex),Process analytics and PAT (PATsmart, SoloVPE, ZipChip, REBEL), |
| GETINGE AB | Sweden | Public Company | Acute Care Therapies (ECMO, ventilation, monitoring, ICU infrastructure, drainage),Surgical Workflows (OR tables, lights, anesthesia, OR integration, sterile supply management),Life Science (low-temperature sterilization, biocontainment, terminal sterilization, isolation, bioprocess solutions), |
| BD | United States | Public Company | Medical Essentials (syringes, needles, IV and vascular access, sharps, enteral),Connected Care (infusion systems, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery, pharma solutions), |
| PERKINELMER INC. | United States | Public Company | Diagnostics (prenatal, neonatal, infectious disease, immunodiagnostics),Life science reagents and research tools,Instruments and imaging systems, |
Patheon Inc is a Netherlands-based private company with 9,100 employees operating in the pharmaceutical and biotechnology sector.
Allergan PLC is an Ireland-incorporated private company founded in 1983 with 17,400 employees, operating in the pharmaceutical and specialty healthcare industry.
Eiken Chemical Co., Ltd. is a Japanese public company founded in 1939 with 696 employees, engaged in chemical and diagnostic product manufacturing.
MaxCyte, Inc is a United States-based public company founded in 1998 with 91 employees, focused on cell engineering and life sciences technology.
Thermo Fisher Scientific Inc. is a United States public company founded in 1956 with 125,000 employees, serving as a global leader in life sciences and laboratory services.
Danaher Corporation is a United States public company founded in 1969 with 59,000 employees, operating across diversified industrial and life sciences sectors.
Merck KGaA is a German public company founded in 1668 with 59,077 employees, operating as a global pharmaceutical, chemical, and life sciences enterprise.
Sartorius AG is a German public company founded in 1870 with 14,242 employees, specializing in laboratory and bioprocess equipment and services.
Corning Incorporated is a United States public company founded in 1851 with 67,200 employees, manufacturing specialty glass and advanced materials for multiple industries.
Lonza is a Swiss public company founded in 1897 with 20,000 employees, providing pharmaceutical and biotechnology manufacturing and life sciences solutions.
Terumo Corporation is a Japanese public company founded in 1921 with 30,591 employees, specializing in medical devices and blood management products.
Eppendorf SE is a German private company founded in 1945 with 4,358 employees, manufacturing laboratory equipment and consumables for life sciences research.
Fujifilm Corporation is a Japanese public company founded in 1934 with 73,526 employees, operating across imaging, healthcare, and materials technology sectors.
Bio-Techne is a United States public company founded in 1976 with 3,100 employees, providing life sciences tools and reagents for research and diagnostics.
Repligen Corporation is a United States public company founded in 1981 with 2,000 employees, specializing in bioprocess chromatography and filtration technologies.
Getinge AB is a Swedish public company founded in 1904 with 11,754 employees, manufacturing medical devices and systems for healthcare and life sciences.
BD is a United States public company founded in 1897 with 72,000 employees, serving as a global leader in medical technology and diagnostic solutions.
PerkinElmer Inc. is a United States public company founded in 1937 with 11,000 employees, providing diagnostics, life sciences, and applied services solutions.
The US cell expansion market was valued at $2,865.8 million in 2024 and is projected to reach $5,597.1 million by 2029.
The US cell expansion market is growing at a compound annual growth rate (CAGR) of 14.3% from 2024 to 2029.
Key drivers include FDA approvals of cell therapies, increasing demand for personalized medicine, adoption of automated bioreactor systems, and significant venture capital investment in US biotech companies.
The US 14.3% CAGR exceeds the global 13.3% rate, positioning the US as the primary growth engine for North American cell expansion innovation and commercialization.
Advanced bioreactor technologies, automated cell culture systems, scalable manufacturing platforms, and contract manufacturing organization (CMO) capacity expansion are key technology drivers in the US market.
This research study involved the extensive use of secondary sources, directories, and databases to identify and collect valuable information for the analysis of the global cell expansion market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was then triangulated with inputs from primary research to arrive at the final market size.
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the cell expansion market. The secondary sources used for this study include World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), US Food and Drug Administration (FDA), South African Medical Research Council, International Society for Cell & Gene Therapy (ISCT), International Business Magazine, Nasdaq, Center for Strategic & International Studies (CSIS), American Society of Gene & Cell Therapy, Statista; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; press releases; trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Extensive primary research was conducted after acquiring basic knowledge about the global cell expansion market scenario through secondary research. Several primary interviews were conducted with market experts from the demand side, such as pharmaceutical and biopharmaceutical companies, research & academic institutes, hospitals & diagnostic laboratories, CROs, and CMOs, and experts from the supply side, such as C-level and D-level executives, product managers, marketing & sales managers of key manufacturers, distributors, and channel partners. These interviews were conducted across six major regions, including the Asia Pacific, North America, Europe, Latin America, Middle East, and Africa. Approximately 60% and 40% of the primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews.

To know about the assumptions considered for the study, download the pdf brochure
Both top-down and bottom-up approaches were used to estimate and validate the total size of the cell expansion market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

To know about the assumptions considered for the study, Request for Free Sample Report
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.

After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Cell expansion is a process of increasing the number of cells through cell division. Cell expansion is often used for research and therapeutic applications. Cell expansion is also used for manufacturing of cell based therapies such as tissue engineering, cell & gene therapy, and regenerative medicine.
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Full forecast, segment splits, and company analysis for all Cell Expansion Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report